Search Results | Molecular Cancer Therapeutics | American Association for Cancer Research

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Growth Inhibition and Induction of Innate Immune Signaling of Chondrosarcomas with Epigenetic Inhibitors

Tahir N. Sheikh, Xiao Chen, Xinjing Xu, John T. McGuire, Matthew Ingham, Chao Lu, Gary K. Schwartz

Mol Cancer Ther (2021) 20 (12): 2362–2371.

DOI: https://doi.org/10.1158/1535-7163.MCT-21-0066

Published: 03 December 2021

View article

Includes: Supplementary data

Journal Articles

Genomic Profiling of Metastatic Uveal Melanoma and Clinical Results of a Phase I Study of the Protein Kinase C Inhibitor AEB071

Sophie Piperno-Neumann, James Larkin, Richard D. Carvajal, Jason J. Luke, Gary K. Schwartz, F. Stephen Hodi, Marie-Paule Sablin, Alexander N. Shoushtari, Sebastian Szpakowski, Niladri Roy Chowdhury, A. Rose Brannon, Thiruvamoor Ramkumar, Leanne de Koning, Adnan Derti, Caroline Emery, Padmaja Yerramilli-Rao, Ellen Kapiteijn

Mol Cancer Ther (2020) 19 (4): 1031–1039.

DOI: https://doi.org/10.1158/1535-7163.MCT-19-0098

Published: 02 April 2020

View article

Includes: Supplementary data

Journal Articles

Preclinical Evaluation of Nintedanib, a Triple Angiokinase Inhibitor, in Soft-tissue Sarcoma: Potential Therapeutic Implication for Synovial Sarcoma

Parag P. Patwardhan, Elgilda Musi, Gary K. Schwartz

Mol Cancer Ther (2018) 17 (11): 2329–2340.

DOI: https://doi.org/10.1158/1535-7163.MCT-18-0319

Published: 02 November 2018

View article

Includes: Supplementary data

Journal Articles

Abstract C49: Phase 1 study of CB-839, a first-in-class, orally administered small molecule inhibitor of glutaminase in patients with refractory solid tumors

Funda Meric-Bernstam, Angela DeMichele, Melinda L. Telli, Pamela Munster, Keith W. Orford, George D. Demitri, Gary K. Schwartz, Othon Iliopoulos, James W. Mier, Taofeek K. Owonikoko, Mark K. Bennett, Manish R. Patel, Jeffery R. Infante, James J. Harding

Mol Cancer Ther (2015) 14 (12_Supplement_2): C49.

DOI: https://doi.org/10.1158/1535-7163.TARG-15-C49

Published: 01 December 2015

View article

Journal Articles

Pilot Trial of Selecting Molecularly Guided Therapy for Patients with Non–V600 BRAF-Mutant Metastatic Melanoma: Experience of the SU2C/MRA Melanoma Dream Team

Mol Cancer Ther (2015) 14 (8): 1962–1971.

DOI: https://doi.org/10.1158/1535-7163.MCT-15-0153

Published: 05 August 2015

View article

Journal Articles

MLN0128, an ATP-Competitive mTOR Kinase Inhibitor with Potent In Vitro and In Vivo Antitumor Activity, as Potential Therapy for Bone and Soft-Tissue Sarcoma

Emily K. Slotkin, Parag P. Patwardhan, Shyamprasad D. Vasudeva, Elisa de Stanchina, William D. Tap, Gary K. Schwartz

Mol Cancer Ther (2015) 14 (2): 395–406.

DOI: https://doi.org/10.1158/1535-7163.MCT-14-0711

Published: 09 February 2015

View article

Includes: Supplementary data

Journal Articles

Overexpression of DDX43 Mediates MEK Inhibitor Resistance through RAS Upregulation in Uveal Melanoma Cells

Grazia Ambrosini, Raya Khanin, Richard D. Carvajal, Gary K. Schwartz

Mol Cancer Ther (2014) 13 (8): 2073–2080.

DOI: https://doi.org/10.1158/1535-7163.MCT-14-0095

Published: 05 August 2014

View article

Includes: Supplementary data

Journal Articles

The Phosphoinositide 3-Kinase α Selective Inhibitor BYL719 Enhances the Effect of the Protein Kinase C Inhibitor AEB071 in GNAQ/GNA11-Mutant Uveal Melanoma Cells

Elgilda Musi, Grazia Ambrosini, Elisa de Stanchina, Gary K. Schwartz

Mol Cancer Ther (2014) 13 (5): 1044–1053.

DOI: https://doi.org/10.1158/1535-7163.MCT-13-0550

Published: 05 May 2014

View article

Includes: Supplementary data

Journal Articles

Crizotinib, a c-Met Inhibitor, Prevents Metastasis in a Metastatic Uveal Melanoma Model

Oliver Surriga, Vinagolu K. Rajasekhar, Grazia Ambrosini, Yildrim Dogan, Ruimin Huang, Gary K. Schwartz

Mol Cancer Ther (2013) 12 (12): 2817–2826.

DOI: https://doi.org/10.1158/1535-7163.MCT-13-0499

Published: 05 December 2013

View article

Includes: Supplementary data

Journal Articles

Inhibition of Mutant GNAQ Signaling in Uveal Melanoma Induces AMPK-Dependent Autophagic Cell Death

Grazia Ambrosini, Elgilda Musi, Alan L. Ho, Elisa de Stanchina, Gary K. Schwartz

Mol Cancer Ther (2013) 12 (5): 768–776.

DOI: https://doi.org/10.1158/1535-7163.MCT-12-1020

Published: 08 May 2013

View article

Includes: Supplementary data

Journal Articles

The Checkpoint Kinase Inhibitor AZD7762 Potentiates Chemotherapy-Induced Apoptosis of p53-Mutated Multiple Myeloma Cells

Heather J. Landau, Samuel C. McNeely, Jayasree S. Nair, Raymond L. Comenzo, Takashi Asai, Hillel Friedman, Suresh C. Jhanwar, Stephen D. Nimer, Gary K. Schwartz

Mol Cancer Ther (2012) 11 (8): 1781–1788.

DOI: https://doi.org/10.1158/1535-7163.MCT-11-0949

Published: 08 August 2012

View article

Includes: Supplementary data

Journal Articles

AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies

Mol Cancer Ther (2008) 7 (9): 2955–2966.

DOI: https://doi.org/10.1158/1535-7163.MCT-08-0492

Published: 11 September 2008

View article

Includes: Supplementary data

Journal Articles

Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells

Grazia Ambrosini, Haider S. Cheema, Sharon Seelman, Allison Teed, Elliot B. Sambol, Samuel Singer, Gary K. Schwartz

Mol Cancer Ther (2008) 7 (4): 890–896.

DOI: https://doi.org/10.1158/1535-7163.MCT-07-0518

Published: 15 April 2008

View article

Journal Articles

Flavopiridol Enhances the Effect of Docetaxel in Vitro and in Vivo in Human Gastric Cancer Cells

Monica Motwani, Carina Rizzo, Francis Sirotnak, Yuhong She, Gary K. Schwartz

Mol Cancer Ther (2003) 2 (6): 549–555.

Published: 01 June 2003

View article

NARROW

Growth Inhibition and Induction of Innate Immune Signaling of Chondrosarcomas with Epigenetic Inhibitors

Genomic Profiling of Metastatic Uveal Melanoma and Clinical Results of a Phase I Study of the Protein Kinase C Inhibitor AEB071

Preclinical Evaluation of Nintedanib, a Triple Angiokinase Inhibitor, in Soft-tissue Sarcoma: Potential Therapeutic Implication for Synovial Sarcoma

Abstract C49: Phase 1 study of CB-839, a first-in-class, orally administered small molecule inhibitor of glutaminase in patients with refractory solid tumors

Pilot Trial of Selecting Molecularly Guided Therapy for Patients with Non–V600 BRAF-Mutant Metastatic Melanoma: Experience of the SU2C/MRA Melanoma Dream Team

MLN0128, an ATP-Competitive mTOR Kinase Inhibitor with Potent In Vitro and In Vivo Antitumor Activity, as Potential Therapy for Bone and Soft-Tissue Sarcoma

Overexpression of DDX43 Mediates MEK Inhibitor Resistance through RAS Upregulation in Uveal Melanoma Cells

The Phosphoinositide 3-Kinase α Selective Inhibitor BYL719 Enhances the Effect of the Protein Kinase C Inhibitor AEB071 in GNAQ/GNA11-Mutant Uveal Melanoma Cells

Crizotinib, a c-Met Inhibitor, Prevents Metastasis in a Metastatic Uveal Melanoma Model

Inhibition of Mutant GNAQ Signaling in Uveal Melanoma Induces AMPK-Dependent Autophagic Cell Death

The Checkpoint Kinase Inhibitor AZD7762 Potentiates Chemotherapy-Induced Apoptosis of p53-Mutated Multiple Myeloma Cells

AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies

Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells

Flavopiridol Enhances the Effect of Docetaxel in Vitro and in Vivo in Human Gastric Cancer Cells

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only